Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.06
-0.00 (-8.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-956727.00 · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-60.7%
↓Gross Margin
22.7%
↓Debt/Equity
0.56
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+236.3%
FCF CAGR
—
FCF margin
-17.3%
FCF / Net income
1.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $12.1M · net income $-1.8M · FCF $-2.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $12.1M | $12.1M | $9.9M | $4.7M | $318763.00 |
| Net Income | $-1.8M | $-1.8M | $-2.8M | $-2.1M | $-4.6M |
| EBITDA | $-1.1M | $-1.1M | $-2.1M | $-1.5M | $-4.3M |
| EPS | -0.02 | -0.02 | -0.04 | -0.03 | -0.09 |
| Gross Margin | 22.7% | 22.7% | 20.1% | 27.3% | -6.4% |
| Operating Margin | -10.1% | -10.1% | -15.1% | -35.5% | -808.2% |
| Net Margin | -15.2% | -15.2% | -27.9% | -43.7% | -1447.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.56 | 0.56 | 0.59 | 0.38 | 0.15 |
| Current Ratio | 0.74 | 0.74 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.1M | $-2.1M | $-395930.00 | $-956727.00 | $-2.7M |
| Returns | |||||
| ROE | -60.7% | -60.7% | -99.9% | -48.8% | -73.5% |
| Valuation | |||||
| P/B | 1.64 | 1.64 | 1.85 | 0.83 | 0.80 |
| Growth & Yield | |||||
| Revenue Growth | 22.2% | 22.2% | 109.2% | 1388.2% | — |
| EPS Growth | 50.0% | 50.0% | -33.3% | 66.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.04 → -0.02
Residual
+10.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.